荣昌生物（09995）今日盘中大涨7.41%，引起市场广泛关注。截至发稿，该股报118.8港元，成交额达4.76亿港元。
消息面上，荣昌生物的眼科创新药伊立芙普α（RC28）已向国家药品监督管理局药品审评中心（CDE）申报上市，用于治疗糖尿病黄斑水肿（DME）。值得注意的是，今年8月，荣昌生物与参天制药全资子公司参天中国达成协议，将伊立芙普α在大中华区及多个亚洲国家的独家开发、生产和商业化权利授予后者，总交易金额高达12.95亿元。这一重大进展显示了公司在眼科领域的创新能力和商业价值。
此外，荣昌生物还将在即将召开的2025年欧洲肿瘤内科学会（ESMO）年会上展示11项原创研究成果。其中，维迪西妥单抗联合治疗一线尿路上皮癌的RC48-C016Ⅲ期临床研究入选最新突破摘要（LBA）。公司还将展示涵盖尿路上皮癌、胃癌、妇科肿瘤等领域的10项多个瘤种及相关治疗策略的最新数据。这些研究成果的展示进一步彰显了荣昌生物在肿瘤治疗领域的研发实力和创新能力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.